New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback